FINWIRES · TerminalLIVE
FINWIRES

研究快讯:林德第一季度业绩超出预期,区域差异显著,项目进展顺利

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:林德公司公布第一季度调整后每股收益为4.33美元,同比增长10%,超出市场预期0.06美元;销售额为88亿美元,同比增长8%,超出预期2%。3%的销售额增长主要由价格上涨和销量增长组成,但调整后的营业利润率下降10个基点至30.0%。业绩表明,尽管欧洲制造业疲软,管理层仍能有效控制价格,并高效完成创纪录的71亿美元项目积压订单。管理层重申了2026年全年调整后每股收益预期为17.60美元至17.90美元(增长7%至9%)。美洲地区销售额强劲增长10%,利润率也得到提升;亚太地区销售额增长11%,电子产品销量增长6%。欧洲、中东和非洲地区面临挑战,销售额下降2%。林德通过分红和股票回购向股东返还了15亿美元。我们认为,林德以积压订单驱动的增长模式能够支撑其盈利持续增长,项目启动速度加快,资本回报率维持在24%,但利润率收缩和销量下滑限制了其近期市盈率扩张的潜力。

Related Articles

Research

Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.

$INCY
Australia

GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease

GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%

$GSK
International

ISM US Manufacturing Index Indicates Steady Expansion in April

The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.